Dr. Schwartz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 Howard Ave
Bldg
New Haven, CT 06519Phone+1 203-785-4176Fax+1 203-785-5886
Education & Training
- University of Texas Health Science Center at HoustonResidency, Obstetrics and Gynecology, 1974 - 1975
- University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 1973 - 1975
- Yale-New Haven Medical CenterResidency, Obstetrics and Gynecology, 1967 - 1971
- University of Kentucky College of Medicine (Bowling Green)Internship, Transitional Year, 1966 - 1967
- Albert Einstein College of MedicineClass of 1966
Certifications & Licensure
- CA State Medical License 1971 - Present
- CT State Medical License 1968 - 2025
- TX State Medical License 1973 - 1985
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2003-2014
- America's Top Doctors Castle Connolly, 2002-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Join now to see all
Clinical Trials
- Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Publications & Presentations
PubMed
- 128 citationsRandomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas ...Amanda N. Fader, Dana M. Roque, Eric R. Siegel, Natalia Buza, Pei Hui
Clinical Cancer Research. 2020-08-01 - 273 citationsRandomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Fact...Amanda N. Fader, Dana M. Roque, Eric R. Siegel, Natalia Buza, Pei Hui
Journal of Clinical Oncology. 2018-03-27 - 377 citationsMolecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance.Ayesha B. Alvero, Rui Chen, Han-Hsuan Fu, Michele K. Montagna, Peter E. Schwartz
Cell Cycle. 2009-01-01
Journal Articles
- Hospital Variation in Responses to Safety Warnings About Power Morcellation in HysterectomyVrunda B Desai, Peter E Schwartz, American Journal of Obstetrics and Gynecology
Press Mentions
- In Memoriam: Peter E. Schwartz, MDOctober 21st, 2024
- Study Validates Combination Therapy for Aggressive Endometrial CancerJune 26th, 2020
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: